Companies › Monopar Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MNPR-101-DFO*-89Zr Humanized IgG1 monoclonal antibody against PD-L1, conjugated to Zirconium-89 radioisotope | – | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| MNPR-101-PCTA-177Lu Lutetium-177 labeled radiopharmaceutical targeting MNPR-101 antigen | – | Phase 1 | Solid Tumor, Adult | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06337084 | MNPR-101-DFO*-89Zr | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT06617169 | MNPR-101-PCTA-177Lu | Phase 1 | Solid Tumor, Adult | Oncology | Jan 2027 |
Cash and short-term investments of $105m on 2026-06-30; operating cash outflow about $14m a year; runway about 93 months at that burn, to Mar 2034
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.